Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study).
Sawada R, Nishioka N, Kim YH, Kiyomi F, Uchino J, Takayama K. Sawada R, et al. Among authors: kiyomi f. Transl Lung Cancer Res. 2023 Aug 30;12(8):1802-1806. doi: 10.21037/tlcr-23-109. Epub 2023 Aug 14. Transl Lung Cancer Res. 2023. PMID: 37691860 Free PMC article.
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).
Iwasaku M, Uchino J, Yamada T, Chihara Y, Shimamoto T, Tamiya N, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: kiyomi f. Transl Lung Cancer Res. 2019 Aug;8(4):519-523. doi: 10.21037/tlcr.2019.08.03. Transl Lung Cancer Res. 2019. PMID: 31555524 Free PMC article.
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
Yamada T, Uchino J, Chihara Y, Shimamoto T, Iwasaku M, Tamiya N, Kaneko Y, Kiyomi F, Takayama K. Yamada T, et al. Among authors: kiyomi f. Ther Adv Med Oncol. 2020 May 28;12:1758835920927841. doi: 10.1177/1758835920927841. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32536981 Free PMC article.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: kiyomi f. Cancer Med. 2023 Jul;12(14):15117-15127. doi: 10.1002/cam4.6184. Epub 2023 Jun 3. Cancer Med. 2023. PMID: 37269194 Free PMC article. Clinical Trial.
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Yamada T, Goto Y, Tanaka H, Kimura H, Minato K, Gyotoku H, Honda T, Watanabe S, Morimoto K, Kiyomi F, Uchino J, Takayama K. Yamada T, et al. Among authors: kiyomi f. Eur J Cancer. 2023 Dec;195:113373. doi: 10.1016/j.ejca.2023.113373. Epub 2023 Oct 22. Eur J Cancer. 2023. PMID: 37890349 Free article. Clinical Trial.
Comparison of the cytokine adsorption ability in continuous renal replacement therapy using polyethyleneimine-coated polyacrylonitrile (AN69ST) or polymethylmethacrylate (PMMA) hemofilters: a pilot single-center open-label randomized control trial.
Nakamura Y, Hatomoto H, Yamasaki S, Yamauchi K, Kiyomi F, Hoshino K, Kawano Y, Nakano T, Hasegawa T, Ishikura H. Nakamura Y, et al. Among authors: kiyomi f. Eur J Med Res. 2023 Jun 30;28(1):208. doi: 10.1186/s40001-023-01184-6. Eur J Med Res. 2023. PMID: 37391846 Free PMC article. Clinical Trial.
33 results